Demographics and characteristics after propensity score weighting
| Parameters | Beta-blockers (n=34 253) | No beta-blockers (n=9365) |
| Demographics | ||
| Age, years, median (IQR) | 64 (56–71) | 65 (57–74) |
| Sex, female, n (%) | 8595 (25.1) | 2536 (27.1) |
| Smoking, n (%) | 10 820 (32.0) [483] | 2494 (27.4) [256] |
| Medical history 1 year after MI, n (%) | ||
| Hypertension | 13 152 (38.4) | 3530 (37.7) |
| Diabetes mellitus | 4601 (13.4) | 1108 (11.8) |
| Atrial fibrillation/flutter | 2250 (6.6) | 635 (6.8) |
| Prior MI* | 1501 (4.4) | 806 (8.6) |
| Prior PCI* | 882 (2.6) | 546 (5.8) |
| Prior CABG* | 418 (1.2) | 244 (2.6) |
| Cerebrovascular disease | 1765 (5.2) | 659 (7.0) |
| Peripheral vascular disease | 824 (2.4) | 329 (3.5) |
| COPD | 957 (2.8) | 367 (3.9) |
| Index event, n (%) | ||
| NSTEMI | 21 310 (62.2) [6] | 6511 (69.5) [1] |
| STEMI | 12 937 (37.8) | 2853 (30.5) |
| In-hospital course and medication at discharge | ||
| eGFR, median (IQR) | 77 (67–89) [1388] | 78 (68–90) [335] |
| PCI, n (%) | 27 383 (79.9) | 6637 (70.9) |
| CABG, n (%) | 1236 (3.6) | 218 (2.3) |
| Beta-blockers, n (%) | 32 757 (95.7) [28] | 4848 (51.8) [5] |
| Concomitant medication 1 year after MI, n (%) | ||
| Acetylsalicylic acid | 32 548 (95.0) | 8555 (91.4) |
| P2Y12 inhibitors | 5808 (17.0) | 1421 (15.2) |
| Oral anticoagulants | 539 (1.6) | 142 (1.5) |
| ACE inhibitors | 11 448 (33.4) | 2349 (25.1) |
| ARB | 4050 (11.8) | 1095 (11.7) |
| Statins | 31 154 (91.0) | 7493 (80.0) |
*Data about prior MI, PCI and CABG were collected at the time of hospitalisation for MI. Values are in median (IQR) for continuous variables and numbers (%) for categorical variables. Numbers within square brackets indicate number of missing values. eGFR levels are based on the Chronic Kidney Disease Epidemiology Collaboration (CKD‐EPI) equation and are presented in ml/min/1.73 m2.
ACE, angiotensin-converting enzyme; ARB, angiotensin-receptor blocker; CABG, coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; IQR, interquartile range; MI, myocardial infarction; NSTEMI, non-ST-segment elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction.